Study #2023-0025
A phase 1 study evaluating SC291, a hypoimmune allogeneic CD19-directed CAR T cell therapy, in relapsed and/or refractory B-cell malignancies (ARDENT)
MD Anderson Study Status
Not Accepting
Treatment Agent
SC291
Description
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study phase:
Phase I
Physician name:
Sattva Neelapu
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-855-743-4745
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.